Price movement over the last 24 hours
ADMA Biologics Inc vs Endeavour Silver Corp — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Endeavour Silver Corp trades at $7.57 (market cap $2.37B). The key difference: ADMA Biologics Inc and Endeavour Silver Corp are close in size by market cap, and Endeavour Silver Corp is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EXK | |
|---|---|---|
Market Cap | $2.13B | $2.37B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $14.12 |
52-Week Low | $7.60 | $4.84 |
Enterprise Value | $2.20B | $2.38B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Endeavour Silver (EXK) trades at $8.51, down 0.58% on the day, with a neutral technical signal and bearish moving averages. The company reported strong Q1 2026 results with earnings of $0.21 per share beating expectations, driven by record production. However, full-year 2025 showed a net loss of $119.10 million despite revenue growth. Recent news highlights high-grade mineralization discoveries at its Terronera mine, supporting future production potential.
The outlook is mixed: analyst consensus is strongly bullish (78.57% buy ratings), but profitability remains a concern with negative margins. Key risks include execution on growth projects and silver price volatility. Upside catalysts hinge on sustained operational improvements and favorable commodity markets.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →